Skip to main content

Mark A. Socinski, MD

Mark A. Socinski, MD

Executive Medical Director of the AdventHealth Cancer Institute, Medical Oncologist

, , , , , , , , , , , , , , , Cancer, ,

Mark A. Socinski

Overview

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Articles

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

JOURNAL OF THORACIC ONCOLOGY

2022

['Poziotinib in Non-Small-Cell Lung Cancer Harboring', 'Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.']

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

EXPERT OPINION ON INVESTIGATIONAL DRUGS

2022

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

2022

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

JOURNAL OF CLINICAL ONCOLOGY

2022

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

JOURNAL FOR IMMUNOTHERAPY OF CANCER

2022

Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

ANNALS OF ONCOLOGY

2021

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

FRONTIERS IN ONCOLOGY

2021

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

JOURNAL OF CLINICAL ONCOLOGY

2021

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer ABOUND.sqm): A Phase III Randomized Clinical Trial

CLINICAL LUNG CANCER

2021

Education & Training

Education

University of Vermont, Burlington, VT

Residency

Harvard Medical School/Beth Israel Hospital, Boston

Fellowship

Harvard Medical School/Beth Israel Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT03833154

A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Icon for trial | D9103C00001 A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-

AstraZeneca AB is doing this research to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy. ...

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Icon for trial | BGB-A317-A1217-302 A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Met

This study is currently enrolling.

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...

NCT03631199

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

Icon for trial | CACZ885U2301 A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic

The purpose of the study is to evaluate how safe and effective canakinumab in combination with other drugs (pembrolizumab and platinum-based doublet chemotherapy) already commonly used to treat lung cancer is. The purpose is al ...